ANUP MARKI

Marki Bio is a biotechnology company dedicated to developing next-generation, off-the-shelf cell therapies using induced pluripotent stem cell (iPSC) technology. Founded by industry veteran Anup Marki, the company aims to create universal donor cells that can be mass-produced and engineered for enhanced therapeutic potency. Their platform focuses on overcoming the logistical and financial barriers of traditional autologous CAR-T therapies by providing standardized, ready-to-use treatments. Marki Bio's approach involves precise genome editing to enhance the persistence and efficacy of its cell products. The company's pipeline is primarily directed toward addressing unmet needs in oncology and autoimmune disorders.